Pancreatic Cancer Research

ResearcherWuhan Union HospitalActive in the last 2 years

Tao Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4340-5767; OpenAlex author ID A5083566143. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 9

  1. RRM2 promotes liver metastasis of pancreatic cancer by stabilizing YBX1 and activating the TGF-beta pathway. Last author DOI 10.1016/j.isci.2024.110864↗
  2. MIB1 upregulates IQGAP1 and promotes pancreatic cancer progression by inducing ST7 degradation. Last author DOI 10.1002/1878-0261.12955↗
  3. MAL2 interacts with IQGAP1 to promote pancreatic cancer progression by increasing ERK1/2 phosphorylation. Last author DOI 10.1016/j.bbrc.2021.02.146↗
  4. FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jcb.29468↗
  5. PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer. Last author DOI 10.1186/s13046-019-1466-7↗
  6. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. Co-author DOI 10.1074/jbc.m116.764407↗
  7. Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-κB signaling pathway. Last author DOI 10.1186/s12943-017-0627-6↗
  8. MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway. Last author DOI 10.18632/oncotarget.5317↗
  9. ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2011.10.033↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xin Jin · 5 shared papers, 2017–2021 · strength 0.56
  2. Xiang Chao Cheng · 2 shared papers, 2021 · strength 0.36
  3. Bin Zhang · 2 shared papers, 2020–2021 · strength 0.32
  4. Rui Fang · 2 shared papers, 2019–2020 · strength 0.25
  5. Wei Li · 1 shared paper, 2024 · strength 0.24
  6. Zhouyuan Du · 1 shared paper, 2024 · strength 0.24
  7. Haixin Yu · 1 shared paper, 2024 · strength 0.24
  8. Ping Fan · 3 shared papers, 2017–2019 · strength 0.24
  9. Bin Zhang · 1 shared paper, 2021 · strength 0.19
  10. Heshui Wu · 3 shared papers, 2015–2017 · strength 0.19
  11. Wei Zhou · 3 shared papers, 2012–2017 · strength 0.15
  12. Shanmiao Gou · 3 shared papers, 2012–2017 · strength 0.15
  13. Chunyou Wang · 2 shared papers, 2012–2015 · strength 0.09
  14. Chong Yang · 1 shared paper, 2017 · strength 0.07
  15. Tao Yin · 1 shared paper, 2017 · strength 0.06
  16. Li Wang · 1 shared paper, 2017 · strength 0.06
  17. Haijiao Yan · 1 shared paper, 2015 · strength 0.05
  18. Tongling Wang · 1 shared paper, 2012 · strength 0.03
  19. Li Wang · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.